

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Gut

54, 1121-1125

DOI: [10.1136/gut.2004.049460](https://doi.org/10.1136/gut.2004.049460)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Lymphoma After Imuran and 6-MP: A New Look. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 41, 683-684.	1.8	1
2	Risks and benefits of azathioprine therapy. <i>Gut</i> , 2005, 54, 1055-1059.	12.1	20
3	Incidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1025-1029.	4.4	24
4	Toxicity of infliximab in the course of treatment of Crohn's disease. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 9-16.	2.4	26
5	Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1017-1024.	4.4	130
6	Update in the treatment of paediatric ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1907-1918.	1.8	4
7	Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 675-712.	2.2	39
8	Infliximab in Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 821-836.	2.2	15
9	Case Report: Lymphoma Arising in an Ileal Pouch Anal Anastomosis After Immunomodulatory Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1030-1034.	4.4	47
10	Systemic Treatment of Patients Who Have Colorectal Cancer and Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 713-727.	2.2	13
11	Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 837-855.	2.2	76
12	Cancer in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 621-639.	2.2	46
13	Predictors of Crohn's Disease. <i>Gastroenterology</i> , 2006, 130, 650-656.	1.3	795
14	American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2006, 130, 940-987.	1.3	397
15	Increased Risk of Lymphoma Among Inflammatory Bowel Disease Patients Treated With Azathioprine and 6-Mercaptopurine. <i>Yearbook of Gastroenterology</i> , 2006, 2006, 123-124.	0.1	0
16	Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 669-677.	2.2	85
17	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, i-xii.	1.9	0
18	Review article: thiopurines in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 715-729.	3.7	149

#	ARTICLE	IF	CITATIONS
19	Review article: medical therapy for fistulizing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1283-1293.	3.7	40
20	Review article: altering the natural history of Crohn's disease ? evidence for and against current therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 25, 061016063002002-???	3.7	101
21	Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population-based study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 205-211.	1.9	188
22	Diagnosis and treatment of hepatic sarcoidosis. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 475-483.	0.8	60
23	Safety of biologics in inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 221-233.	0.8	10
24	Genetics of inflammatory bowel disease and associated cancers. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 191-199.	0.5	2
25	Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. <i>Current Gastroenterology Reports</i> , 2006, 8, 499-505.	2.5	11
26	Immunomodulation with AZA/6-MP/MTX: Current Use in IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, S24-S25.	1.8	2
27	Ulcerative colitis: diagnosis and management. <i>BMJ: British Medical Journal</i> , 2006, 333, 340-343.	2.3	57
28	Natalizumab: a promising treatment for Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 677-689.	3.0	1
29	European evidence based consensus on the diagnosis and management of Crohn's disease: current management. <i>Gut</i> , 2006, 55, i16-i35.	12.1	533
30	Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. <i>Gut</i> , 2006, 55, 228-233.	12.1	123
31	Medical Management of Crohn's Disease in 2006: What's on the Horizon?. <i>American Journal of Gastroenterology</i> , 2007, 102, S2-S6.	0.4	2
32	Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 686-694.	1.7	107
33	Recent advances in the medical therapy of Crohn's disease in childhood. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2553-2568.	1.8	4
34	Are we ready for top-down therapy for inflammatory bowel diseases: con. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 249-255.	3.0	1
35	Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. <i>Gut</i> , 2007, 56, 1181-1183.	12.1	44
36	Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. , 2007, , CD006443.		45

#	ARTICLE	IF	CITATIONS
37	Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, 2804-2812.	0.4	99
38	Meta-Analysis of Risk of Malignancy with Immunosuppressive Drugs in Inflammatory Bowel Disease. <i>Annals of Pharmacotherapy</i> , 2007, 41, 21-28.	1.9	79
39	Remission and relapse of Crohn's disease following autologous haematopoietic stem cell transplantation for non-Hodgkin's lymphoma. <i>Gut</i> , 2007, 56, 1325-1325.	12.1	18
40	Maintenance of Medically Induced Remission of Crohn's Disease. <i>Digestion</i> , 2007, 76, 116-129.	2.3	12
41	Drug Safety in Crohn's Disease Therapy. <i>Digestion</i> , 2007, 76, 161-168.	2.3	18
42	Biological therapies in inflammatory bowel disease: top-down or bottom-up?. <i>Current Opinion in Gastroenterology</i> , 2007, 23, 395-399.	2.3	46
43	“Mind the Gap”. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 799-809.	2.2	18
44	Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. , 2007, , CD006320.		32
46	Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, , CD000478.		95
47	Inflammatory bowel disease: clinical aspects and established and evolving therapies. <i>Lancet, The</i> , 2007, 369, 1641-1657.	13.7	1,593
48	Diagnosis and management of inflammatory bowel disease in children. <i>Seminars in Pediatric Surgery</i> , 2007, 16, 164-171.	1.1	36
49	Cancer and pediatric inflammatory bowel disease. <i>Seminars in Pediatric Surgery</i> , 2007, 16, 205-213.	1.1	22
51	Management of Steroid-Dependent Ulcerative Colitis: Immunomodulatory Agents, Biologics, or Surgery?. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 668-671.	4.4	9
52	Thiopurine Treatment in Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2007, 46, 187-208.	3.5	145
53	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1410-1413.	1.3	48
54	Current Medical Therapy for Chronic Inflammatory Bowel Diseases. <i>Surgical Clinics of North America</i> , 2007, 87, 697-725.	1.5	17
55	Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients. <i>Drugs</i> , 2007, 67, 1167-1198.	10.9	333
56	Crohn's Disease Patients' Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. <i>Gastroenterology</i> , 2007, 133, 769-779.	1.3	167

#	ARTICLE	IF	CITATIONS
58	Crohn's Disease: Advise and Consent. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 791-793.	1.7	0
59	Safety of biologic therapy. Inflammatory Bowel Diseases, 2007, 13, 769-796.	1.9	34
60	Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark. Inflammatory Bowel Diseases, 2007, 13, 481-489.	1.9	340
61	Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 896-902.	1.9	84
62	Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?. Inflammatory Bowel Diseases, 2007, 13, 1024-1030.	1.9	217
63	Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?. Inflammatory Bowel Diseases, 2007, 13, 1299-1307.	1.9	107
64	Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy?. Alimentary Pharmacology and Therapeutics, 2007, 26, 1019-1024.	3.7	71
65	Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Alimentary Pharmacology and Therapeutics, 2007, 26, 987-1003.	3.7	93
66	Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2008, 27, 220-227.	3.7	81
67	New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. European Journal of Clinical Pharmacology, 2007, 63, 875-878.	1.9	24
69	Review Article: Multiple Myeloma and Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2007, 52, 2022-2028.	2.3	13
70	Treatment of perianal fistula and abscess: Crohn's and non-Crohn's. Current Treatment Options in Gastroenterology, 2007, 10, 211-220.	0.8	12
71	Radiation doses from small-bowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease. Pediatric Radiology, 2008, 38, 285-291.	2.0	79
72	Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Current Gastroenterology Reports, 2008, 10, 302-307.	2.5	2
73	Biologic therapy for inflammatory bowel disease comes of age. Current Gastroenterology Reports, 2008, 10, 565-567.	2.5	0
75	Azathioprine prescribing in neurology. Journal of Neurology, 2008, 255, 791-795.	3.6	4
76	Survival in Danish patients with breast cancer and inflammatory bowel disease: A nationwide cohort study. Inflammatory Bowel Diseases, 2008, 14, 519-525.	1.9	30
77	Adverse events of IBD therapies. Inflammatory Bowel Diseases, 2008, 14, S210-S211.	1.9	10

#	ARTICLE	IF	CITATIONS
78	Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 606-613.	3.7	22
79	Autoimmune and inflammatory disorders and risk of malignant lymphomas – an update. <i>Journal of Internal Medicine</i> , 2008, 264, 514-527.	6.0	128
80	Cancer in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 378.	3.3	280
81	120 Crohn's Disease: Factors Associated with Exposure to High Levels of Diagnostic Radiation. <i>Gastroenterology</i> , 2008, 134, A-20.	1.3	82
83	Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2008, 134, 929-936.	1.3	913
84	Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?. <i>Gastroenterology</i> , 2008, 135, 1442-1447.	1.3	112
85	Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2008, 40, S236-S246.	0.9	9
86	Clinical course of ulcerative colitis. <i>Digestive and Liver Disease</i> , 2008, 40, S247-S252.	0.9	32
87	Infliximab in Crohn's disease: early and long-term treatment. <i>Digestive and Liver Disease</i> , 2008, 40, S271-S279.	0.9	14
88	Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 93-96.	1.3	4
89	Current treatment of inflammatory bowel disease in children. <i>Digestive and Liver Disease</i> , 2008, 40, 16-21.	0.9	14
90	Research and clinical challenges in paediatric inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2008, 40, 32-38.	0.9	16
91	Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. <i>Digestive and Liver Disease</i> , 2008, 40, 144.	0.9	8
93	Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the $\alpha 4\beta 7$ Integrin. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1370-1377.	4.4	283
94	Predictors of severe Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 948-954.	1.5	270
95	Hepatosplenic T cell lymphoma in inflammatory bowel disease. <i>Gut</i> , 2008, 57, 1639-1641.	12.1	137
96	Inflammatory Bowel Disease in Older People. <i>Journal of Pharmacy Practice and Research</i> , 2008, 38, 234-238.	0.8	1
97	Therapeutic options in acute severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 357-370.	3.0	16

#	ARTICLE	IF	CITATIONS
98	Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. <i>Gut</i> , 2008, 57, 1524-1529.	12.1	307
99	Changing Epidemiology and Risk Factors for Gastrointestinal Non-Hodgkin's Lymphoma in a North American Population: Population-Based Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 1762-1769.	0.4	48
100	Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1428-1435.	0.4	88
101	Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon- α . <i>Leukemia and Lymphoma</i> , 2008, 49, 1420-1423.	1.3	19
102	The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease. <i>Journal of Immunotoxicology</i> , 2008, 5, 179-187.	1.7	24
103	Specific considerations in the treatment of pediatric inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 105-124.	3.0	9
104	Adverse events of IBD therapies. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S210-S211.	1.9	5
105	Predicting the Need for Azathioprine at First Presentation in Children With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2008, 47, 123-129.	1.8	14
106	Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies. <i>Personalized Medicine</i> , 2008, 5, 609-626.	1.5	3
108	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008, 22, 261-272.	1.7	10
109	Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. <i>World Journal of Gastroenterology</i> , 2008, 14, 3937.	3.3	367
110	Treatment of inflammatory bowel disease: A review of medical therapy. <i>World Journal of Gastroenterology</i> , 2008, 14, 354.	3.3	201
111	Hepatosplenic T cell lymphoma following infliximab therapy for Crohn's disease. <i>Medical Journal of Australia</i> , 2009, 190, 341-342.	1.7	6
112	Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. <i>Clinical and Experimental Gastroenterology</i> , 2009, , 149.	2.3	1
113	Infliximab: A Review of its Use in the Treatment of Crohn's Disease. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2250.	0.1	0
114	Mutagenicity and Potential Carcinogenicity of Thiopurine Treatment in Patients with Inflammatory Bowel Disease. <i>Cancer Research</i> , 2009, 69, 7004-7012.	0.9	48
115	Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. <i>Gut</i> , 2009, 58, 1427-1436.	12.1	66
116	Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 2524-2533.	0.4	188

#	ARTICLE	IF	CITATIONS
117	Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 2566-2571.	0.4	56
118	Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. <i>American Journal of Gastroenterology</i> , 2009, 104, 2760-2767.	0.4	114
119	Noncolorectal Malignancies in Inflammatory Bowel Disease: More than Meets the Eye. <i>Digestive Diseases</i> , 2009, 27, 375-381.	1.9	21
120	Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2009, , CD000067.		89
121	Fatal Epstein-Barr Virus Primo Infection in a 25-Year-Old Man Treated with Azathioprine for Crohn's Disease. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1252-1254.	3.9	43
122	Balancing the risks and benefits of prolonged use of infliximab. <i>Gut</i> , 2009, 58, 477-478.	12.1	6
123	Review: Tailoring the treatment to the individual in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 239-244.	3.2	4
125	Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together?. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, S202-S208.	0.9	5
126	Primary central nervous system lymphoma in a patient treated with natalizumab. <i>Annals of Neurology</i> , 2009, 66, 403-406.	5.3	78
127	Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: Are we barking up the wrong tree?. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1281-1282.	1.9	18
128	Adalimumab safety in global clinical trials of patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1308-1319.	1.9	110
129	Risk factors for tumor occurrence in patients with myasthenia gravis. <i>Journal of Neurology</i> , 2009, 256, 1221-1227.	3.6	29
130	Factors associated with radiation exposure in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1128-1136.	3.7	64
131	A 69-YEAR-OLD MAN WITH LEFT HEMISPHERIC NECROTIZING MASS LESION. <i>Brain Pathology</i> , 2009, 19, 541-544.		1
132	Is there truly a risk of lymphoma from biologic therapies?. <i>Dermatologic Therapy</i> , 2009, 22, 418-430.	1.7	55
133	Serum sickness, encephalitis and other complications of anti-cytokine therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2009, 23, 101-112.	2.4	45
134	Emerging drugs for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 505-521.	2.4	24
135	Medical management of Crohn's disease: A guide for radiologists. <i>European Journal of Radiology</i> , 2009, 69, 371-374.	2.6	2

#	ARTICLE	IF	CITATIONS
137	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 433-436.	17.8	39
138	Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. , 2009, , CD006320.		41
139	Hepatosplenic T-cell lymphoma and TNF- α inhibitors. <i>Expert Review of Hematology</i> , 2009, 2, 611-614.	2.2	9
140	Salmonella osteomyelitis in an immunocompromized patient presenting as a primary lymphoma of the bone. <i>International Journal of Infectious Diseases</i> , 2009, 13, e67-e70.	3.3	7
141	Immunosuppression-associated lymphoma in IBD. <i>Lancet, The</i> , 2009, 374, 1572-1573.	13.7	9
142	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Lancet, The</i> , 2009, 374, 1617-1625.	13.7	996
143	Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , 2009, 104, 465-483.	0.4	883
144	Risk of Lymphoma Associated With Combination Anti- α Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 874-881.	4.4	459
145	Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 80-85.	4.4	152
146	Safety Profile of IBD: Lymphoma Risks. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 669-689.	2.2	12
147	Health-Related Quality-of-Life Evaluation of Crohn Disease Patients After Receiving Natalizumab Therapy. <i>Gastroenterology Nursing</i> , 2009, 32, 327-339.	0.4	15
148	Use of biologic agents in pediatric inflammatory bowel disease. <i>Current Opinion in Pediatrics</i> , 2009, 21, 646-650.	2.0	1
149	Hepatocellular Carcinoma and Crohn's Disease: A Case Report and Review. <i>Internal Medicine</i> , 2009, 48, 815-819.	0.7	9
150	Systemic Lupus Erythematosus and Right Leg Weakness. <i>Canadian Journal of Neurological Sciences</i> , 2009, 36, 98-101.	0.5	2
151	Infliximab in the treatment of pediatric Crohn's disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 15-22.	0.2	2
152	Medical Therapy for Inflammatory Bowel Disease in Children and Adolescents. <i>Pediatric and Adolescent Medicine</i> , 2009, , 158-171.	0.4	0
153	Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, 257-267.	1.8	40
154	Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?. <i>Current Drug Targets</i> , 2010, 11, 179-186.	2.1	35

#	ARTICLE	IF	CITATIONS
155	Epstein-Barr Virus-associated Lymphoproliferative Disorder in Crohn Disease Treated With Azathioprine. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 51, 229-231.	1.8	7
157	New pathophysiological insights and modern treatment of IBD. <i>Journal of Gastroenterology</i> , 2010, 45, 571-583.	5.1	170
158	Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?. <i>Current Gastroenterology Reports</i> , 2010, 12, 471-478.	2.5	44
159	The good, the bad, and the ugly. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1443-1444.	1.9	0
160	Safety of infliximab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2109-2116.	1.9	37
161	Adverse effects of biologics used for treating IBD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 167-182.	2.4	175
162	Summary of worldwide pediatric malignancies reported after exposure to etanercept. <i>Pediatric Rheumatology</i> , 2010, 8, 18.	2.1	41
163	Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 119-130.	3.7	88
164	Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1017-1022.	3.7	19
165	Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. <i>Internal Medicine Journal</i> , 2010, 40, 139-149.	0.8	11
167	Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2840.	0.4	1
168	The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 7-16.	2.5	21
169	Review: Immunomodulators for all patients with inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 31-42.	3.2	27
170	Optimising use of thiopurines in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2010, 1, 44-51.	1.8	9
171	Thiopurine therapy in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 575-588.	3.0	19
172	Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 107-114.	2.5	6
173	Administrative Database Studies in IBD: A Cautionary Tale. <i>American Journal of Gastroenterology</i> , 2010, 105, 1808-1810.	0.4	11
174	Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease in the Setting of Immunosuppression for Solid Organ Transplantation. <i>American Journal of Gastroenterology</i> , 2010, 105, 1210-1211.	0.4	23

#	ARTICLE	IF	CITATIONS
175	Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Review of Clinical Immunology, 2010, 6, 621-631.	3.0	41
176	Lymphoma With Central Nervous System Involvement in a Young Patient With Crohn Disease Treated With Azathioprine. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 790-792.	1.8	3
177	Epstein-Barr Virus, Lymphoma Risk and the Potential Role of HIV Infection in IBD Patients Undergoing Immunosuppression. Digestive Diseases, 2010, 28, 519-524.	1.9	11
178	Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab. Leukemia and Lymphoma, 2010, 51, 174-177.	1.3	4
179	State-of-the-Art: Immunosuppression and Biologic Therapy. Digestive Diseases, 2010, 28, 536-542.	1.9	34
180	Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety, 2010, 9, 573-592.	2.4	38
181	Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case-Control Study. American Journal of Gastroenterology, 2010, 105, 1604-1609.	0.4	143
182	What is the optimal therapy for Crohn's disease: step-up or top-down?. Expert Review of Gastroenterology and Hepatology, 2010, 4, 167-180.	3.0	36
183	6-Thioguanine and 6-Methylthioguanine Are Mutagenic in Human Cells. ACS Chemical Biology, 2010, 5, 1021-1027.	3.4	32
184	Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies. BioDrugs, 2010, 24, 3-14.	4.6	84
185	Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety, 2010, 9, 379-382.	2.4	6
186	A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. Journal of Crohn's and Colitis, 2010, 4, 221-256.	1.3	87
187	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis, 2010, 4, 28-62.	1.3	1,247
188	Hepatosplenic T-cell lymphoma and inflammatory bowel disease. Journal of Crohn's and Colitis, 2010, 4, 511-522.	1.3	93
189	Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. Journal of Crohn's and Colitis, 2010, 4, 683-686.	1.3	11
190	Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology, 2010, 105, 501-523.	0.4	1,080
191	Hepatosplenic T-Cell Lymphoma in a Young Man With Crohn's Disease: Case Report and Literature Review. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 144-148.	0.4	63
192	Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Annals of the Rheumatic Diseases, 2010, 69, 400-408.	0.9	190

#	ARTICLE	IF	CITATIONS
194	Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 659-666.	3.0	22
195	The potential for disease modification in Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 79-85.	17.8	80
196	Safety Profile of IBD: Lymphoma Risks. <i>Medical Clinics of North America</i> , 2010, 94, 93-113.	2.5	5
197	Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 449-450.e1.	4.4	30
198	A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 36-41.e1.	4.4	422
199	Thiopurines for Inflammatory Bowel Disease: Time to Engage With Dermatologists?. <i>Gastroenterology</i> , 2011, 141, 1549-1551.	1.3	5
200	Medical and surgical therapy of inflammatory bowel disease in the elderly " Prospects and complications. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 177-188.	1.3	51
201	Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 608-611.	1.3	9
202	Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease" Proceedings of the first Thiopurine Task Force meeting. <i>Digestive and Liver Disease</i> , 2011, 43, 270-276.	0.9	41
203	Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2011, 106, 2146-2153.	0.4	201
204	Azathioprine. <i>Neurology</i> , 2011, 77, 659-666.	1.1	236
205	Chemoprevention of colorectal cancer in inflammatory bowel disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 593-606.	2.4	31
206	Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2011, 60, 571-607.	12.1	1,127
207	Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. <i>Life Sciences</i> , 2011, 89, 269-275.	4.3	10
208	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics. <i>American Journal of Gastroenterology</i> , 2011, 106, 214-223.	0.4	188
209	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1594-1602.	0.4	71
210	Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 4166.	3.3	79
211	Lymphomas of the Esophagus, Gastrointestinal Tract, Hepatobiliary Tract, and Pancreas. , 2011, , 133-196.		0

#	ARTICLE	IF	CITATIONS
213	Thiopurine Methyltransferase Predicts the Extent of Cytotoxicity and DNA Damage in Astroglial Cells after Thioguanine Exposure. PLoS ONE, 2011, 6, e29163.	2.5	8
214	Pediatric Inflammatory Bowel Disease and Imaging-related Radiation: Are We Increasing the Likelihood of Malignancy?. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 280-285.	1.8	40
215	Inflammatory bowel disease therapy: current state-of-the-art. Current Opinion in Gastroenterology, 2011, 27, 1.	2.3	32
216	Review article: explaining risks of inflammatory bowel disease therapy to patients. Alimentary Pharmacology and Therapeutics, 2011, 33, 23-32.	3.7	101
217	British Association of Dermatologists's™ guidelines for the safe and effective prescribing of azathioprine 2011. British Journal of Dermatology, 2011, 165, 711-734.	1.5	107
218	Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine, 2011, 270, 15-28.	6.0	34
219	Cutaneous Lymphoproliferative Disorder Complicating Infectious Mononucleosis in an Immunosuppressed Patient. Pediatric Dermatology, 2011, 28, 149-155.	0.9	1
220	Incidence and Risk Factors for Lymphoma in a Single-Center Inflammatory Bowel Disease Population. Digestive Diseases and Sciences, 2011, 56, 1489-1495.	2.3	12
221	Azathioprine as an alternative treatment in primary hypophysitis. Pituitary, 2011, 14, 16-22.	2.9	18
222	Coexistence of spinal schwannoma with unusual malignant peripheral T-cell lymphoma within a lumbar spine lesion. Acta Neurochirurgica, 2011, 153, 1723-1724.	1.7	1
223	Update on the Management of Crohn's™ Disease. Current Gastroenterology Reports, 2011, 13, 465-474.	2.5	26
224	Azathioprine in ulcerative colitis: Why, when, how and how long to use it. Drug Development Research, 2011, 72, 733-738.	2.9	2
225	Clinical course of Crohn's™ disease following treatment of lymphoma. Inflammatory Bowel Diseases, 2011, 17, 1265-1269.	1.9	9
226	Optimizing thiopurine therapy in inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1428-1435.	1.9	33
227	Primary intestinal lymphoma in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1557-1563.	1.9	21
228	Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflammatory Bowel Diseases, 2011, 17, 1837-1845.	1.9	88
229	Tolerance and efficacy of azathioprine in pediatric Crohn's™ disease. Inflammatory Bowel Diseases, 2011, 17, 2138-2143.	1.9	49
230	Response to Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2011 [Epub ahead of print].. Inflammatory Bowel Diseases, 2011, 17, E161-E162.	1.9	0

#	ARTICLE	IF	CITATIONS
231	Successful treatment of asymptomatic or clinically terminal bovine <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone. <i>Virulence</i> , 2011, 2, 131-143.	4.4	37
232	Splenic Littoral Cell Hemangioendothelioma in a Patient With Crohn's Disease Previously Treated With Immunomodulators and Anti-TNF Agents: A Rare Tumor Linked to Deep Immunosuppression. <i>American Journal of Gastroenterology</i> , 2011, 106, 1863-1865.	0.4	13
233	Precursor T-lymphoblastic lymphoma presenting as primary renal lymphoma with acute renal failure. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 289-291.	2.9	5
234	Biologics in Paediatric Crohn's Disease. <i>Gastroenterology Research and Practice</i> , 2011, 2011, 1-10.	1.5	8
235	A Burkitt's Lymphoma Case Mimicking Crohn's Disease: A Case Report. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4.	0.7	8
236	Update on systemic therapies for atopic dermatitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 421-426.	2.3	40
237	Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. <i>Immunotherapy</i> , 2012, 4, 883-898.	2.0	81
238	Immunosuppression-Related Lymphomas and Cancers in IBD: How Can They Be Prevented?. <i>Digestive Diseases</i> , 2012, 30, 415-419.	1.9	17
239	Lymphoma in Inflammatory Bowel Disease and Treatment Decisions. <i>American Journal of Gastroenterology</i> , 2012, 107, 964-970.	0.4	17
240	Immunosuppression in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 341-348.	2.3	9
241	Management of Pediatric Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 340-361.	1.8	320
242	Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2012, , CD000478.		78
243	Immunosuppression in Patients with Crohn's Disease and Neoplasia. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 1008-1011.	1.3	4
244	Diffuse Large B-cell Lymphoma Arising Primarily at the Stoma After Bladder Reconstruction Using Ileal Conduit. <i>Internal Medicine</i> , 2012, 51, 643-646.	0.7	5
245	Immunosuppressive and biologic therapy for ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 449-467.	2.4	18
246	Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 46-51.	4.4	45
247	Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor 1 α Agents for Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 411-428.	2.2	7
248	Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1315-1325.e4.	4.4	54

#	ARTICLE	IF	CITATIONS
249	Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 391-399.e1.	4.4	234
250	Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. <i>Gut</i> , 2012, 61, 235-240.	12.1	132
251	Mesentery lymphoma in a patient with Crohn's disease: An extremely rare entity. <i>International Journal of Surgery Case Reports</i> , 2012, 3, 343-345.	0.6	3
252	An Unusual Cause of Lower Gastrointestinal Bleeding in Crohn's Disease. <i>Gastroenterology</i> , 2012, 142, 1421-1623.	1.3	0
253	Hepatosplenic gamma-delta T-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 283-292.	4.4	51
254	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 116-131.	1.3	18
255	Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 578-587.	1.3	28
256	Treatment of neuromyelitis optica: Review and recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 180-187.	2.0	217
257	Circulating Antibodies against Bacterial Wall Products: Are There Arguments for Early Immunosuppression?. <i>Digestive Diseases</i> , 2012, 30, 55-66.	1.9	61
259	Pediatric ulcerative colitis: current treatment approaches including role of infliximab. <i>Biologics: Targets and Therapy</i> , 2012, 6, 125.	3.2	22
261	Epstein-Barr Virus-Negative Aggressive Natural Killer-Cell Leukaemia with High P-Glycoprotein Activity and Phosphorylated Extracellular Signal-Regulated Protein Kinases 1 and 2. <i>Hematology Reports</i> , 2012, 4, e16.	0.8	9
262	Lymphoma risk in children and young adults with inflammatory bowel disease: Analysis of a large single-center cohort. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 838-843.	1.9	50
263	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1608-1616.	1.9	36
264	Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1855-1858.	1.9	25
265	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2063-2071.	1.9	96
266	Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. <i>Gut</i> , 2012, 61, 476-483.	12.1	70
267	Chronic hepatitis. , 2012, , 992-998.e1.		0
268	Managing Risks of Neoplasia in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2012, 14, 174-180.	2.5	6

#	ARTICLE	IF	CITATIONS
269	Hepatosplenic \hat{I}^2 T-cell lymphoma associated with azathioprine therapy. <i>International Journal of Hematology</i> , 2012, 95, 592-594.	1.6	8
270	^{18}F -FDG positron emission tomography: potential utility in the assessment of Crohn's disease. <i>Abdominal Imaging</i> , 2012, 37, 377-386.	2.0	18
271	Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 385-389.	2.8	94
272	Meta-analysis: diagnostic medical radiation exposure in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 529-539.	3.7	79
273	Reversal of UVA Skin Photosensitivity and DNA Damage in Kidney Transplant Recipients by Replacing Azathioprine. <i>American Journal of Transplantation</i> , 2012, 12, 218-225.	4.7	77
274	When to use biological agents in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1141-1149.	2.8	12
275	Anti-TNF Therapy Is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 92-98.	1.9	7
276	Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. <i>Biologics in Therapy</i> , 2013, 3, 1-14.	1.8	5
277	Recent Advances Using Immunomodulators for Inflammatory Bowel Disease. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 575-588.	2.0	37
278	Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study. <i>Gastroenterology</i> , 2013, 145, 1007-1015.e3.	1.3	201
279	Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 167-174.	1.3	23
280	Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease. <i>American Journal of Epidemiology</i> , 2013, 177, 1296-1305.	3.4	196
281	Cumulative Radiation Dose from Medical Imaging in Chronic Adult Patients. <i>American Journal of Medicine</i> , 2013, 126, 480-486.	1.5	27
282	American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease. <i>Gastroenterology</i> , 2013, 145, 1464-1478.e5.	1.3	196
283	Cancer risk in immune-mediated inflammatory diseases (IMID). <i>Molecular Cancer</i> , 2013, 12, 98.	19.2	104
284	Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data. <i>Patient</i> , 2013, 6, 241-255.	2.7	36
285	Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD. <i>American Journal of Gastroenterology</i> , 2013, 108, 1835-1842.	0.4	97
286	State-of-the-art medical prevention of postoperative recurrence of Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 413-422.	17.8	42

#	ARTICLE	IF	CITATIONS
287	A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. <i>Blood</i> , 2013, 122, 3713-3722.	1.4	116
288	Tumor necrosis factor $\hat{\pm}$ inhibitor therapy and cancer risk in chronic immune-mediated diseases. <i>Arthritis and Rheumatism</i> , 2013, 65, 48-58.	6.7	110
289	Is There Still a Role for Thiopurines in Crohn's Disease?. <i>Gastroenterology</i> , 2013, 145, 714-716.	1.3	11
290	Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell Lymphoma: A Single Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 8-14.	0.4	71
291	Reassessing the Risks and Benefits of Thiopurines in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 395-397.	4.4	0
292	The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 385-391.	1.3	24
293	Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study. <i>Gastroenterology and Hepatology</i> , 2013, 36, 616-623.	0.5	6
294	New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe. <i>Digestive and Liver Disease</i> , 2013, 45, 269-276.	0.9	41
295	Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 24-30.	2.8	75
296	T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF- $\hat{\pm}$) Inhibitors: Results of the REFURBISH Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 99-105.	0.4	193
297	Immunotherapeutics for Autoimmune Encephalopathies and Dementias. <i>Current Treatment Options in Neurology</i> , 2013, 15, 723-737.	1.8	33
298	Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin. <i>Biochemical Pharmacology</i> , 2013, 85, 798-807.	4.4	89
299	Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents. <i>BioDrugs</i> , 2013, 27, 585-590.	4.6	21
300	Do Inflammatory Bowel Disease Therapies Cause Cancer?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1306-1321.	1.9	51
301	Nonneoplastic Diseases of the Small Intestine: Differential Diagnosis and Crohn Disease. <i>American Journal of Roentgenology</i> , 2013, 201, W174-W182.	2.2	8
302	Enteral Nutrition in Crohn's Disease: An Underused Therapy. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-11.	1.5	25
303	Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1002-1024.	3.7	63
304	Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1405-1413.	1.5	80

#	ARTICLE	IF	CITATIONS
305	The impact of abdominal computed tomography in a tertiary referral centre emergency department on the management of patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 513-521.	3.7	40
306	Temporal trends in imaging and associated radiation exposure in inflammatory bowel disease. <i>International Journal of Clinical Practice</i> , 2013, 67, 1057-1065.	1.7	23
307	Effects of Infliximab and Hydrocortisone on In Vitro Cytokine Responses after Stimulation with Lipopolysaccharide. <i>Surgical Infections</i> , 2013, 14, 30-34.	1.4	8
308	Current concepts in the diagnosis and management of autoimmune hepatitis. <i>Frontline Gastroenterology</i> , 2013, 4, 2-11.	1.8	2
309	Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 117-127.	3.0	6
310	No Increase in Epstein-Barr Virus Viral Load in a Group of 30 Asymptomatic Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, 1933-1935.	0.4	5
311	Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis. <i>Frontline Gastroenterology</i> , 2013, 4, 205-209.	1.8	5
312	Diagnostic Medical Radiation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2501-2508.	1.9	22
313	Epstein-Barr Virus in Inflammatory Bowel Disease Correlation with Different Therapeutic Regimens. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1710-1716.	1.9	43
315	Safety of Thiopurine Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1404-1410.	1.9	243
316	Targeted Inhibition of Vav1 Activity Does Not Favour Development of Colitis-Associated Colon Cancer. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E72-E73.	1.9	0
317	More on Lymphoproliferative Disorders Associated With Crohn Disease Treatments. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 131-132.	1.8	1
318	Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1384-1389.	1.9	36
319	Role of Thiopurine Metabolite Testing and Thiopurine Methyltransferase Determination in Pediatric IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, 333-340.	1.8	39
320	Extraintestinal Hodgkin Disease in a Young Man With Crohn Disease Treated With Multiple Immunosuppressive Therapies. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 248-249.	1.8	3
321	Quantifying Exposure to Diagnostic Radiation and Factors Associated With Exposure to High Levels of Radiation in Korean Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	25
323	Use of thiopurines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 1040.	3.3	32
324	Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease. <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2013, 16, 65.	1.2	17

#	ARTICLE	IF	CITATIONS
325	Familial Adenomatous Polyposis and Crohn's Disease in One Patient: Dilemmas and Concerns. Case Reports in Gastroenterology, 2013, 7, 358-362.	0.6	4
326	EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?. BMJ Case Reports, 2013, 2013, bcr2013200423-bcr2013200423.	0.5	18
328	Anaplastic Large Cell Lymphoma of the Colon in a Patient with Colonic Crohn Disease Treated with Infliximab and Methotrexate. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 11-12.	1.9	8
329	Immunosuppressive therapies for inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 3146.	3.3	79
330	Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases. Paediatric Drugs, 2014, 16, 343-352.	3.1	10
331	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 9675.	3.3	70
332	Inflammatory Bowel Disease and Neoplasia in Children. Digestive Diseases, 2014, 32, 455-462.	1.9	3
333	Autoimmune disease, tumor necrosis factor inhibitors and acute leukemia: possible associations in two patients?. Leukemia and Lymphoma, 2014, 55, 1697-1698.	1.3	2
335	Case 39-2014. New England Journal of Medicine, 2014, 371, 2418-2427.	27.0	15
336	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Alimentary Pharmacology and Therapeutics, 2014, 39, 459-477.	3.7	129
337	Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops. Inflammatory Bowel Diseases, 2014, 20, 926-935.	1.9	29
338	Patient Preferences for Surgical Versus Medical Therapy for Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 103-114.	1.9	67
339	Retrospective Cohort Study of Methotrexate Use in the Treatment of Pediatric Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1341-1345.	1.9	37
340	Treatment of ulcerative colitis. Current Opinion in Gastroenterology, 2014, 30, 84-96.	2.3	35
341	Cumulative radiation dose estimates from medical imaging in paediatric patients with non-oncologic chronic illnesses. A systematic review. Physica Medica, 2014, 30, 403-412.	0.7	19
342	Positioning Therapy for Crohn's Disease. Current Gastroenterology Reports, 2014, 16, 384.	2.5	0
343	Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiology and Drug Safety, 2014, 23, 735-744.	1.9	63
344	Review article: anti-adhesion therapies for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 579-594.	3.7	155

#	ARTICLE	IF	CITATIONS
345	Targeting TNF- α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy, 2014, 14, 75-101.	3.1	119
347	Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2014, 15, 1659-1670.	1.8	14
348	Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT α , ϕ Registry. American Journal of Gastroenterology, 2014, 109, 212-223.	0.4	160
349	Use of azathioprine in IBD: modern aspects of an old drug. Gut, 2014, 63, 1695-1699.	12.1	32
350	Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. The Cochrane Library, 2014, 2014, CD006320.	2.8	99
352	Reply. Gastroenterology, 2014, 147, 540-541.	1.3	0
353	Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. BMC Gastroenterology, 2014, 14, 127.	2.0	16
354	Hematologic malignancies in the Japanese patients with inflammatory bowel disease. Journal of Gastroenterology, 2014, 49, 1299-1306.	5.1	16
355	Hodgkin Lymphoma Following Adalimumab for the Treatment of Crohn's Disease in an Adolescent. Digestive Diseases and Sciences, 2014, 59, 2403-2405.	2.3	6
356	Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut, 2014, 63, 1843-1853.	12.1	106
357	Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III). Journal of Crohn's and Colitis, 2014, 8, 31-44.	1.3	130
358	Induction of TGF- β and IL-10 production in dendritic cells using astilbin to inhibit dextran sulfate sodium-induced colitis. Biochemical and Biophysical Research Communications, 2014, 446, 529-534.	2.1	30
359	Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology, 2014, 146, 941-949.e2.	1.3	172
360	6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 735-738.	1.3	4
361	Lymphoma development in patients with autoimmune and inflammatory disorders "What are the driving forces?. Seminars in Cancer Biology, 2014, 24, 61-70.	9.6	150
362	Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Nationwide Population-based Cohort Study With 30 Years of Follow-up Evaluation. Clinical Gastroenterology and Hepatology, 2014, 12, 265-273.e1.	4.4	205
363	Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 1179-1207.	1.3	825
364	The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2014, 43, 525-541.	2.2	39

#	ARTICLE	IF	CITATIONS
365	Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2132-2141.	1.9	16
366	Primary Enteric-Type Mucinous Adenocarcinoma of the Urethra in a Patient With Ulcerative Colitis. <i>International Surgery</i> , 2014, 99, 669-672.	0.1	6
367	Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients. <i>Brain and Behavior</i> , 2015, 5, e00396.	2.2	14
368	Risk of Lymphoma. <i>Frontiers of Gastrointestinal Research</i> , 0, , 143-146.	0.1	0
369	Mortality Associated With Medical Therapy Versus Elective Colectomy in Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 2015, 163, 262-270.	3.9	42
370	Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1847-1853.	1.9	77
371	Cancer and Immunomodulators in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 674-698.	1.9	55
372	Treatment of neuromyelitis optica. <i>Current Opinion in Ophthalmology</i> , 2015, 26, 476-483.	2.9	15
373	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S60-74.	2.0	39
374	Ulcerative Colitis Diagnosed in a Patient after Primary Rectal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Treated. <i>Proceedings of Singapore Healthcare</i> , 2015, 24, 123-129.	0.6	0
375	New Applications for Traditional Drugs in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2948-2957.	1.9	3
376	Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2016, 2016, CD000067.	2.8	184
377	Does a Personal or Family History of Malignancy Preclude the Use of Immunomodulators and Biologics in IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 428-435.	1.9	11
378	Managing refractory Crohn's disease: challenges and solutions. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 131.	2.3	6
379	Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab. <i>Pediatric Health, Medicine and Therapeutics</i> , 2015, 6, 33.	1.6	2
380	Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-18.	1.5	15
381	Management of arthropathy in inflammatory bowel diseases. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 65-77.	2.5	32
382	Overview of Medical Management of Crohn's Disease. , 2015, , 163-171.		0

#	ARTICLE	IF	CITATIONS
383	Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1293-1301.e5.	4.4	65
384	Medical Therapy for Crohn's Disease: The Present. , 2015, , 35-48.		0
385	Considerations and management of a patient with three metachronous cancers in association with Lynch syndrome and ileal Crohn's disease: A case report. <i>International Journal of Surgery Case Reports</i> , 2015, 10, 73-75.	0.6	5
386	A practical guide to the use of thiopurines in oral medicine. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 761-768.	2.7	9
387	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 731-746.	3.0	11
388	Gamma-delta cell lymphomas. <i>European Journal of Haematology</i> , 2015, 94, 206-218.	2.2	69
389	Malignancies in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 81-89.	1.5	14
390	The epidemiology of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 942-951.	1.5	272
391	Epstein-Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 398-403.	1.3	70
392	Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 871-883.	3.2	11
393	Azathioprine treatment of intractable pruritus: A retrospective review. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 439-443.	1.2	29
394	Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 497-505.	3.0	18
395	Optimizing the use of thiopurines in inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 138-146.	2.5	44
396	Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 13-19.	1.6	4
397	Risk and Clinical Characteristics of Lymphoma in Korean Patients With Inflammatory Bowel Diseases. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, e11-e16.	2.2	10
398	Update 2014. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 445-452.	1.9	58
399	Cancers Complicating Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1441-1452.	27.0	488
400	Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3399-3407.	2.3	25

#	ARTICLE	IF	CITATIONS
401	Adalimumab for the treatment of pediatric Crohn's disease. Expert Review of Clinical Immunology, 2015, 11, 963-972.	3.0	6
402	Inflammatory Bowel Disease. Surgical Clinics of North America, 2015, 95, 1105-1122.	1.5	148
403	Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 847-858.e4.	4.4	322
404	The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 177-189.	3.0	27
405	Is Super-Selective Superior?. Journal of Crohn's and Colitis, 2016, 10, 1129-1131.	1.3	0
406	Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 5.	1.1	39
407	Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?. BioMed Research International, 2016, 2016, 1-11.	1.9	25
408	Inflammatory Bowel Disease: Epidemiology. , 2016, , .		1
409	The Evolving Role of Thiopurines for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 234-240.	1.9	7
410	EBV Status and Thiopurine Use in Pediatric IBD. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 711-714.	1.8	60
411	The safety of treatment options for pediatric Crohn's disease. Expert Opinion on Drug Safety, 2016, 15, 1383-1390.	2.4	9
412	Management of Inflammatory Bowel Disease in the Elderly. Current Treatment Options in Gastroenterology, 2016, 14, 285-304.	0.8	22
414	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. The Cochrane Library, 2016, , .	2.8	1
415	Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2733-2747.	1.9	35
417	A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. Journal of Gastroenterology, 2016, 51, 1050-1062.	5.1	30
418	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. Journal of Crohn's and Colitis, 2016, 10, 913-924.	1.3	30
420	Methotrexate in Crohn's disease: a new face for an old drug?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1135-1144.	3.0	4
421	DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 1316-1323.	1.3	46

#	ARTICLE	IF	CITATIONS
422	Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from <i>Chrysanthemum morifolium</i> Ramat by gas chromatography with flame ionization detector. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1029-1030, 88-94.	2.3	50
423	The 100 classic papers in ulcerative colitis: a bibliometric analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1187-1195.	3.0	14
424	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1806-1812.	4.4	15
425	Efectos adversos de los fármacos inmunosupresores de uso común en dermatología. <i>Piel</i> , 2016, 31, 616-622.	0.0	1
426	European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 11, j188.	1.3	79
427	Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, j193.	1.3	28
428	Crohn's Disease Is Associated with the Risk for Thyroid Cancer. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2902-2906.	1.9	14
429	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1339-1349.	1.8	20
430	Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 429-439.	3.1	40
432	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 58-64.	4.4	93
433	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.9	42
434	Multidisciplinary management: Inflammatory bowel disease. <i>British Dental Journal</i> , 2017, 222, 4-5.	0.6	1
435	Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, 1901-1914.e3.	1.3	180
436	Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2017, 239, 115-146.	1.8	73
437	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , 2017, 74, 433-441.	3.3	28
438	Chronic hepatitis. , 2017, , 1058-1064.e2.		0
439	Magnetic Resonance Enterography. , 2017, , 185-203.		0
440	Thiopurines in Crohn's Disease. , 2017, , 321-331.		0

#	ARTICLE	IF	CITATIONS
441	Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Revista De GastroenterologÃa De MÃ©xico (English Edition), 2017, 82, 134-155.	0.2	2
442	Medical Management of Ulcerative Colitis: Conventional Therapyâ€”Azathioprine. , 2017, , 413-419.		2
443	Step-Up vs. Top-Down Approach in Crohnâ€™s Disease. , 2017, , 481-489.		0
444	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. American Journal of Gastroenterology, 2017, 112, 1135-1143.	0.4	27
445	Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study. Journal of Crohn's and Colitis, 2017, 11, 954-962.	1.3	98
446	Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 303-315.	4.5	67
447	Neuromyelitis Optica: Immunopathogenesis, Clinical Manifestations, and Treatments. , 2017, , 187-202.		0
448	The impact of inflammatory bowel disease on oral health. British Dental Journal, 2017, 222, 549-553.	0.6	12
449	Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). Revista De GastroenterologÃa De MÃ©xico, 2017, 82, 134-155.	0.2	4
450	Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factorâ€”Î± inhibitor therapy and literature review. Annals of Diagnostic Pathology, 2017, 26, 16-22.	1.3	33
451	Inflammatory Bowel Disease in Primary Immunodeficiencies. Current Allergy and Asthma Reports, 2017, 17, 57.	5.3	46
452	Inflammatory bowel disease and oral health. BDJ Team, 2017, 4, .	0.1	1
453	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2017, 318, 1679.	7.4	424
454	Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 453-460.	1.9	47
455	Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Alimentary Pharmacology and Therapeutics, 2017, 45, 50-62.	3.7	47
457	Management Challenges in Adolescents with Crohn's Disease-Current Practice. Journal of Inflammatory Bowel Diseases & Disorders, 2017, 02, .	0.1	2
458	Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroidâ€”free elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1485-1491.	2.8	16
459	Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine. Biomedicine and Pharmacotherapy, 2018, 100, 8-14.	5.6	16

#	ARTICLE	IF	CITATIONS
460	Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 305-353.	5.1	427
461	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. <i>Human Pathology</i> , 2018, 74, 5-16.	2.0	77
462	Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. <i>Dermatologic Surgery</i> , 2018, 44, 469-480.	0.8	42
463	Evidence-based consensus on opportunistic infections in inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2018, 19, 54-65.	1.5	2
464	Inflammatory Bowel Disease Across the Age Continuum: Similarity and Disparity. <i>Indian Journal of Pediatrics</i> , 2018, 85, 989-994.	0.8	11
465	Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 732-741.	1.9	29
466	The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 361-368.	1.8	21
467	Epstein-Barr virus positive diffuse large B-cell lymphoma presenting with vaginal sloughing and ulcerated skin nodule. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 162-166.	1.3	4
468	Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease. , 2018, , 101-112.		0
469	Primary diffuse large B-cell lymphoma of the ileal conduit created after radical cystectomy. <i>IJU Case Reports</i> , 2018, 1, 22-24.	0.3	0
470	Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. <i>Frontiers in Pharmacology</i> , 2018, 9, 1107.	3.5	45
471	Colorectal Lymphoma: A Review. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 309-316.	1.1	19
472	Positioning biologics—A case-based discussion: Vedolizumab. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 15-15.	2.8	1
473	Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2018, 16, 182.	1.9	13
474	Epstein-Barr Virus-Positive Mucocutaneous Ulcer in an Immunosuppressed Patient. <i>ACG Case Reports Journal</i> , 2018, 5, e32.	0.4	21
475	Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases. <i>Modern Pathology</i> , 2018, 31, 1457-1469.	5.5	6
476	Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 9-15.	2.4	1
477	Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). <i>Intestinal Research</i> , 2018, 16, 178.	2.6	21

#	ARTICLE	IF	CITATIONS
478	Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1042-1052.	1.3	7
479	Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2018, 21, 1.	1.2	50
480	Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-up in the PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2018, 113, 872-882.	0.4	58
481	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <i>Leukemia Research</i> , 2018, 71, 1-5.	0.8	14
482	Sacral nerve stimulation improves colonic inflammation mediated by autonomic-inflammatory cytokine mechanism in rats. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13676.	3.0	31
483	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459.	1.9	33
484	Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. <i>Journal of International Medical Research</i> , 2019, 47, 3534-3549.	1.0	2
485	Lymphoma Risk and Screening in IBD. , 2019, , 61-73.		0
486	Crohn's Disease and the Risk of Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2019, 32, 305-313.	1.1	8
487	Effects of Human Adipose Tissue-Derived and Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in a Dextran Sulfate Sodium-Induced Mouse Model. <i>BioResearch Open Access</i> , 2019, 8, 185-199.	2.6	17
488	Antioxidant and Anti-Inflammatory Properties of a Thuja occidentalis Mother Tincture for the Treatment of Ulcerative Colitis. <i>Antioxidants</i> , 2019, 8, 416.	5.1	27
489	Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis. <i>Internal Medicine</i> , 2019, 58, 2305-2313.	0.7	1
490	Hepatosplenic $\hat{I}^3\text{-}\hat{I}$ T-Cell Lymphoma: Who Is on Your Speed Dial?. <i>Journal of Oncology Practice</i> , 2019, 15, 307-312.	2.5	8
491	A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. <i>Drugs and Aging</i> , 2019, 36, 607-624.	2.7	5
492	Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 907-918.	3.1	6
493	Genetic Predisposition to Non-Hodgkin Lymphoma. , 2019, , 97-110.		2
494	Management of elderly ulcerative colitis in Japan. <i>Journal of Gastroenterology</i> , 2019, 54, 571-586.	5.1	25
495	Safety of drugs used for the treatment of Crohn's disease. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 357-367.	2.4	29

#	ARTICLE	IF	CITATIONS
497	IBD in the Elderly: Management Challenges and Therapeutic Considerations. <i>Current Gastroenterology Reports</i> , 2019, 21, 60.	2.5	24
498	Solitary extramedullary plasmacytoma of the rectum complicating ulcerative colitis. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 160-165.	0.8	3
499	Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 60-67.	2.3	2
500	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 116-126.	0.4	39
501	The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease. <i>Digestion</i> , 2019, 99, 126-132.	2.3	22
502	Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1-5.	0.8	2
503	Role of Thiopurines in Pediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 70, 825-832.	1.8	13
504	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 617-623.	1.3	26
505	Primary extraperitoneal rectum lymphoma in AIDS patient. <i>Journal of Coloproctology</i> , 2020, 40, 175-178.	0.1	1
506	An unexpected surprise: rare association of neuroendocrine tumours in inflammatory bowel disease. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjaa306.	0.4	0
507	A highly efficient hybrid peptide ameliorates intestinal inflammation and mucosal barrier damage by neutralizing lipopolysaccharides and antagonizing the lipopolysaccharide receptor interaction. <i>FASEB Journal</i> , 2020, 34, 16049-16072.	0.5	7
508	Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2020, 149, 153-159.	2.9	16
509	Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2093722.	0.3	2
510	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. <i>The Cochrane Library</i> , 2020, 8, CD012328.	2.8	7
511	Malignancies in Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 136-145.	2.3	48
512	Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093012.	3.2	5
513	An unusual case of diffuse large B-cell lymphoma complicating a Crohn's disease. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3061-3064.	0.5	3
514	Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1222-1230.	1.3	10

#	ARTICLE	IF	CITATIONS
515	Long-Term Survival After Pelvic Exenteration for Locally Recurrent Rectal Cancer Associated With Crohn's Disease With, Adjuvant Chemotherapy, and Immunosuppressive Therapy. <i>ACG Case Reports Journal</i> , 2020, 7, e00374.	0.4	0
516	Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1324-1335.e2.	4.4	72
517	Management of the Elderly Inflammatory Bowel Disease Patient. <i>Digestion</i> , 2020, 101, 105-119.	2.3	27
518	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1330-1339.	1.9	8
519	Intestinal T-cell lymphoma presenting as colonic perforation in the setting of ulcerative colitis: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 176-180.	0.8	0
520	The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1117-1138.e19.	4.4	44
521	Drug-Induced Malignancy. , 2021, , 700-709.e2.		0
522	Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 170-175.	0.8	2
523	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 840-859.	1.3	33
524	Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report. <i>BMC Surgery</i> , 2021, 21, 50.	1.3	2
525	Management of an uncommon T-Cell lymphoma revealed by an anastomotic dehiscence in Crohn's disease: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 79, 53-57.	0.6	1
526	NUDT15: A bench to bedside success story. <i>Clinical Biochemistry</i> , 2021, 92, 1-8.	1.9	7
527	Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1684-1693.	1.9	14
528	Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults. <i>The Cochrane Library</i> , 0, , .	2.8	1
529	Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies. <i>Translational Andrology and Urology</i> , 2021, 10, 1332-1341.	1.4	12
530	Detection of Chemotherapeutic Drug 6-Mercaptopurine Through Manipulating Localized Surface Plasmon Resonance Absorption of Silver Nanoplates. <i>Nano</i> , 2021, 16, 2150046.	1.0	1
531	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 489-526.	5.1	202
532	Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021, 88, 105174.	1.6	0

#	ARTICLE	IF	CITATIONS
533	Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, 358-362.	1.8	2
534	Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis. <i>Journal of Clinical Neuroscience</i> , 2021, 88, 70-74.	1.5	9
535	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 429-437.	8.1	34
536	Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies. <i>Digestive and Liver Disease</i> , 2021, 53, 809-816.	0.9	11
537	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , 2021, 27, 4276-4297.	3.3	13
538	Stopping Anti-TNF in CD Remitters: Cons. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 1-5.	1.9	0
539	Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 500-505.	1.3	7
540	Psoriasisâ€”A Cancer Risk Factor?. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8366.	2.5	1
541	Risk of Cancer in Pediatric-Onset Inflammatory Bowel Diseases: A Nation-Wide Study from the Epi-Iirn. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
542	Immunosuppressive therapy in SLE. , 2021, , 623-659.		0
543	Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study. <i>European Journal of Neurology</i> , 2021, 28, 1706-1715.	3.3	8
544	Cancer vaccines: translational strategies. , 2021, , 307-328.		0
545	The Natural History of Pediatric Crohn Disease. , 0, , 67-74.		3
546	Step-Up vs. Top-Down Approach in Medical Management of Inflammatory Bowel Disease. , 2012, , 535-547.		1
547	State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators. , 2011, , 93-110.		2
548	Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders. , 2011, , 854-866.		4
552	Lymphomatoid Granulomatosis: A Unique Complication of Crohn Disease and Its Treatment in Pediatrics. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 50, 559-561.	1.8	8
553	Shortâ€”course Ondansetron for the Prevention of Methotrexateâ€”induced Nausea in Children With Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 53, 389-393.	1.8	31

#	ARTICLE	IF	CITATIONS
554	Peripheral T-cell lymphoma in a patient with Crohn's disease. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200606-bcr2013200606.	0.5	1
555	Azathioprine therapy selectively ablates human V α 2+ T cells in Crohn's disease. <i>Journal of Clinical Investigation</i> , 2015, 125, 3215-3225.	8.2	40
556	Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?. <i>F1000Research</i> , 2019, 8, 132.	1.6	11
557	Use of Thiopurines and Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Diseases: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e81487.	2.5	44
559	Therapeutic role of methotrexate in pediatric Crohn's disease. <i>Bosnian Journal of Basic Medical Sciences</i> , 2018, 18, 211-216.	1.0	5
560	Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). <i>International Journal of Nanomedicine</i> , 2007, 2, 39-47.	6.7	17
561	The Management of Paediatric Crohn's Disease: Addressing Unmet Needs. <i>The Open Pediatric Medicine Journal</i> , 2008, 2, 21-29.	1.6	2
562	Controversies in the treatment of Crohn's disease: The case for an accelerated step-up treatment approach. <i>World Journal of Gastroenterology</i> , 2008, 14, 2670.	3.3	25
563	Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 5512.	3.3	40
564	Are we giving azathioprine too much time?. <i>World Journal of Gastroenterology</i> , 2008, 14, 5519.	3.3	7
565	Are we giving biologics too late? The case for early versus late use. <i>World Journal of Gastroenterology</i> , 2008, 14, 5523.	3.3	21
566	Hepatocellular carcinoma occurring in a Crohn's disease patient. <i>World Journal of Gastroenterology</i> , 2010, 16, 3215.	3.3	20
567	Role of conventional therapies in the era of biological treatment in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 1797.	3.3	11
568	Current status of thiopurine analogues in the treatment in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 4372.	3.3	7
569	Use of the tumor necrosis factor-blockers for Crohn's disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 4823.	3.3	30
570	Thiopurines in inflammatory bowel disease revisited. <i>World Journal of Gastroenterology</i> , 2013, 19, 1699.	3.3	47
571	Expert opinion: Experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 2979.	3.3	16
572	Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. <i>World Journal of Gastroenterology</i> , 2013, 19, 4877.	3.3	16

#	ARTICLE	IF	CITATIONS
573	Papillary thyroid cancer and inflammatory bowel disease: Is there a relationship?. World Journal of Gastroenterology, 2013, 19, 1079.	3.3	7
574	Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 857.	3.3	7
575	Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis. World Journal of Gastroenterology, 2014, 20, 16683.	3.3	2
576	Integrin antagonists are effective and safe for Crohn's disease: A meta-analysis. World Journal of Gastroenterology, 2015, 21, 4744-4749.	3.3	7
577	Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis. World Journal of Gastroenterology, 2016, 22, 10471.	3.3	2
578	A case of rapid growing colonic NK/T cell lymphoma complicated by Crohn's disease. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 119-23.	2.2	5
580	Therapy of NMO spectrum disorders. Annals of Indian Academy of Neurology, 2015, 18, 16.	0.5	11
581	Therapeutic efficacy of an elemental diet for patients with crohn's disease and its association with amino acid metabolism. Saudi Journal of Gastroenterology, 2017, 23, 20.	1.1	7
582	Bowel Imaging in IBD Patients: Review of the Literature and Current Recommendations. , 2014, 04, .		2
583	A Potential "Curative" Modality for Crohn's Disease--Modeled after Prophylaxis of Bovine Johne's Disease. Mycobacterial Diseases: Tuberculosis & Leprosy, 2013, 02, .	0.1	2
584	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 181.	1.0	19
585	Combination therapy for inflammatory bowel disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, 8, 103.	1.1	25
586	Radiation Exposure from Abdominal Imaging Studies in Patients with Intestinal Behçet Disease. Gut and Liver, 2014, 8, 380-387.	2.9	7
587	Guidelines for the Management of Crohn's Disease. Intestinal Research, 2012, 10, 26.	2.6	11
588	Management of inflammatory bowel disease in older persons: evolving paradigms. Intestinal Research, 2018, 16, 194.	2.6	21
589	Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intestinal Research, 2021, 19, 419-429.	2.6	13
590	Nasal type natural killer T-cell lymphoma involving nasopharynx and larynx. Kulak Burun Boğaz İhtisas Dergisi: KBB = Journal of Ear, Nose, and Throat, 2014, 24, 364-367.	0.3	1
591	Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease. Clinical Endoscopy, 2014, 47, 509.	1.5	37

#	ARTICLE	IF	CITATIONS
592	Azathioprine: long-term side-effects. , 2006, , 142-151.		0
593	Medical Treatment of Ulcerative Colitis. , 2006, , 229-238.		0
594	Morbus Crohn und Colitis ulcerosa. , 2007, , 933-939.		0
595	Medical Management of Crohn's Disease in 2006. American Journal of Gastroenterology, 2007, 102, 2-6.	0.4	1
596	Biologicals for treatment of patients with inflammatory bowel diseases " quite in fashion or really necessary?. , 2008, , 26-43.		0
597	CROHN'S DISEASE: AETIOLOGY, PATHOLOGY, DIAGNOSIS AND MEDICAL TREATMENT. , 2008, , 1783-1862.		0
598	Traitement de la recto-colite ulcero-hémorragique et de la maladie de Crohn. , 2008, , 247-268.		0
599	INFLAMMATORY BOWEL DISEASES. , 2009, , 487-503.		1
600	INFLAMMATION AND IMMUNOMODULATION. , 2009, , 157-172.		0
601	Immunoregulatory Drugs. , 2009, , 909-927.		1
602	Nouveautés dans la stratégie thérapeutique des maladies inflammatoires chroniques de l'intestin. , 2010, , 181-188.		0
603	Crohn's Disease and Malignant Lymphomas. , 2010, , 275-280.		1
605	Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease. BMJ Case Reports, 2010, 2010, bcr0320102809-bcr0320102809.	0.5	0
606	IBD: Medical Management. , 2011, , 463-478.		0
607	A Case of Hepatosplenic T-cell Lymphoma with Colonic Involvement. Intestinal Research, 2011, 9, 51.	2.6	1
608	Treatment Side Effects and Associated Autoimmune Diseases. , 2012, , 197-216.		0
609	Conventional Medical Management of Crohn's Disease: Azathioprine and 6-Mercaptopurine. , 2012, , 379-385.		0
610	Conventional Medical Management of Ulcerative Colitis: Azathioprine. , 2012, , 473-480.		0

#	ARTICLE	IF	CITATIONS
611	Surgery for Small Bowel Crohn's Disease. , 2012, , 293-309.		0
612	Can azathioprine/6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: What is the most appropriate time for this?. Turkish Journal of Gastroenterology, 2012, 23, 17-20.	1.1	0
614	Crohn's Disease Complicated by Gastrointestinal Non-Hodgkin's Lymphoma: Report of a Case. Journal of Gerontology & Geriatric Research, 2012, 01, .	0.1	0
615	Biologic Agents for Inflammatory Bowel Disease (The Current, the Future and the Controversy). , 0, , .		1
616	Evaluating Lymphoma Risk in Inflammatory Bowel Disease. , 0, , .		0
617	The Natural History of Crohn Disease in Children. , 2013, , 65-71.		0
618	A Case of Hepatosplenic T-cell Lymphoma Diagnosed by Bone Marrow Examination. Laboratory Medicine Online, 2013, 3, 104.	0.2	0
621	Appropriate Administration Timing and Clinical Indications of Thiopurine in Crohn's Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2014, 63, 194.	0.4	0
622	Step-Up Versus Top-Down Therapy in Ulcerative Colitis. , 2014, , 457-467.		0
623	Safety Considerations in the Medical Therapy of Ulcerative Colitis. , 2014, , 297-311.		1
624	Chemoprevention in Ulcerative Colitis. , 2014, , 291-296.		0
625	Antimetabolite Therapy in Ulcerative Colitis: Azathioprine, 6-Mercaptopurine, and Methotrexate. , 2014, , 135-143.		0
626	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2015, , 179-237.	0.0	0
627	I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy. , 2015, , 135-140.		0
628	A Case Followed as Having Multiple Sclerosis but Diagnosed with Secondary Brain Lymphoma. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2015, 21, 131-134.	0.3	0
629	The Risk of Hepatosplenic T-Cell Lymphoma (HSTCL) in Women with Inflammatory Bowel Disease (IBD) on Thiopurines. Journal of Inflammatory Bowel Diseases & Disorders, 2016, 01, .	0.1	0
630	The Natural History of Crohn Disease in Children. , 2017, , 87-94.		0
631	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2017, , 389-400.		0

#	ARTICLE	IF	CITATIONS
632	Coexistence of Crohn's Disease and Hodgkin's Lymphoma in a Young Man with Rectorrhagia. Jundishapur Journal of Chronic Disease Care, 2017, In Press, .	0.3	1
633	Diffuse Large B-cell Lymphoma Occurring from the Rectum Diagnosed by Rectal Perforation That Developed during Treatment of Ulcerative Colitis. Japanese Journal of Gastroenterological Surgery, 2018, 51, 234-244.	0.1	0
634	Traitement de la rectocolite hémorragique et de la maladie de Crohn. , 2018, , 203-232.e1.		0
635	Gastrointestinal Lymphomas. , 2019, , 329-349.		0
636	Enfermedad de Crohn y linfoma primario de intestino delgado: reporte de caso. Revista Colombiana De Gastroenterología, 2019, 34, 85.	0.2	0
637	Fecal microbiota transplantation: the european consensus and first ukrainian experience. Gastroenterology & Hepatology (Bartlesville, Okla), 2019, 10, .	0.1	1
638	Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 5087-5096.	1.7	3
639	Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease. Saudi Journal of Gastroenterology, 2020, 26, 312.	1.1	6
640	<i>NUDT15</i> variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 5420-5428.	5.2	4
641	Epstein-Barr Virus Prevalence at Diagnosis and Seroconversion during Follow-Up in Pediatric Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 5187.	2.4	3
643	Are biologicals safe enough?. , 0, , 245-256.		0
646	Progress in the diagnosis and treatment of inflammatory bowel disease. Gastroenterology and Hepatology, 2011, 7, 3-16.	0.1	12
647	Emerging data in the concomitant use of immunomodulators and biologic therapies. Gastroenterology and Hepatology, 2008, 4, 481-3.	0.1	0
648	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGE Group. Gastroenterology and Hepatology, 2008, 4, 713-20.	0.1	0
649	Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clinical and Experimental Gastroenterology, 2009, 2, 149-61.	2.3	4
650	Predictors of aggressive inflammatory bowel disease. Gastroenterology and Hepatology, 2011, 7, 652-9.	0.1	31
651	Risk of lymphoma in patients with inflammatory bowel disease. Gastroenterology and Hepatology, 2012, 8, 45-7.	0.1	2
652	A Potential 'Curative' Modality for Crohn's Disease--Modeled after Prophylaxis of Bovine Johne's Disease. Mycobacterial Diseases: Tuberculosis & Leprosy, 2012, 2, 117.	0.1	4

#	ARTICLE	IF	CITATIONS
653	Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. <i>Annals of Gastroenterology</i> , 2012, 25, 193-200.	0.6	6
654	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	3.7	3
655	Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, and Lymphoma. , 2022, , 587-604.		1
656	Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 786-795.	1.3	13
657	Mechano-Regulation of Gene Expression in the Gut: Implications in Pathophysiology and Therapeutic Approaches in Obstructive, Inflammatory, and Functional Bowel Disorders. , 2021, , .		1
658	Risk of malignancy in patients with inflammatory bowel disease: A population-based cohort study from China. <i>International Journal of Cancer</i> , 2022, 150, 1770-1778.	5.1	5
659	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
660	Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. <i>Digestion</i> , 2022, 103, 169-173.	2.3	4
661	Biologic therapy for inflammatory bowel disease comes of age. <i>Current Gastroenterology Reports</i> , 2008, 10, 565-6.	2.5	0
664	Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1826-1832.	1.9	21
665	Orphan patients with inflammatory bowel disease - when we treat beyond evidence. <i>World Journal of Gastroenterology</i> , 2021, 27, 8047-8057.	3.3	1
666	Targeting Mechano-Transcription Process as Therapeutic Intervention in Gastrointestinal Disorders. <i>Frontiers in Pharmacology</i> , 2021, 12, 809350.	3.5	5
667	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	3.7	13
671	Use of Azathioprine in Ulcerative Colitis: A Comprehensive Review. <i>Cureus</i> , 2022, , .	0.5	3
672	Drug-induced malignancy. , 2013, , 701-710.e1.		1
674	Inflammatory Bowel Disease and Long-term Risk of Cancer: A Prospective Cohort Study Among Half a Million Adults in UK Biobank. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 384-395.	1.9	8
676	ABSTRACTS: 12th ISoP Annual Meeting "New Landscapes for Pharmacovigilance" Cancun, Mexico 30 October-2 November 2012. <i>Drug Safety</i> , 2012, 35, 877-970.	3.2	0
677	Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. <i>RMD Open</i> , 2022, 8, e002139.	3.8	6

#	ARTICLE	IF	CITATIONS
678	Global research trends of immunotherapy and biotherapy for inflammatory bowel disease: a bibliometric analysis from 2002 to 2021. <i>BioMedical Engineering OnLine</i> , 2022, 21, .	2.7	5
679	Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2565-2582.	1.4	4
680	Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	3
681	Iatrogenic Immunodeficiency Associated Lymphoproliferative Disorder in a Patient With Inflammatory Bowel Disease. <i>Journal of Medical Cases</i> , 2022, 13, 521-524.	0.7	0
682	Impact of Epstein-Barr virus infection in patients with inflammatory bowel disease. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
683	Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5382-5391.	2.3	8
684	Persistently High Rates of Abdominal Computed Tomography Imaging Among Patients With Inflammatory Bowel Disease Who Present to the Emergency Department. <i>Journal of the Canadian Association of Gastroenterology</i> , 2023, 6, 64-72.	0.3	1
685	ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 827-854.	1.3	36
686	Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression. <i>Biomedicines</i> , 2023, 11, 99.	3.2	3
687	Management of inflammatory bowel disease in the elderly: A review. <i>Digestive and Liver Disease</i> , 2023, 55, 1001-1009.	0.9	5
688	Expert consensus on the systemic treatment of atopic dermatitis in special populations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1135-1148.	2.4	24
689	The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2432.	2.4	3
691	Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA). <i>American Journal of Clinical Dermatology</i> , 2023, 24, 405-418.	6.7	1
693	Diffuse large B-cell lymphoma in a patient treated with azathioprine for ulcerative colitis: a case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 2059-2063.	1.1	0
694	Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. <i>BMJ Open Gastroenterology</i> , 2023, 10, e001037.	2.7	3
695	Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis. <i>Internal Medicine Journal</i> , 0, , .	0.8	1
696	Incidence of lymphomas in inflammatory bowel disease: report of an emblematic case, systematic review, and meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
697	SOHO State of the Art Updates and Next Questions Challenging Cases in Rare T-Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 642-650.	0.4	2

#	ARTICLE	IF	CITATIONS
698	Ustekinumab for treatment of refractory ulcerative colitis in an elderly patient: A case report. <i>World Chinese Journal of Digestology</i> , 2023, 31, 515-520.	0.1	1
699	Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. <i>Cytokine and Growth Factor Reviews</i> , 2023, 71-72, 1-12.	7.2	12
700	Prevalence of immunomodulator use as combination therapy with vedolizumab or ustekinumab in inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2023, , .	2.5	0
701	Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review. <i>Cancers</i> , 2023, 15, 3824.	3.7	3
702	Updates in NMOSD and MOGAD Diagnosis and Treatment. <i>Neurologic Clinics</i> , 2023, , .	1.8	1
703	Long-term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real-world experience. <i>JGH Open</i> , 2023, 7, 599-609.	1.6	4
705	A primary hepatic lymphoma in a patient with Crohn's disease receiving thiopurine and anti-TNF therapy: a case report. <i>Future Science OA</i> , 0, , .	1.9	2
707	The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
708	Current Treatment Strategies for Inflammatory Bowel Disease Patients at the Risk of Developing Cancer: A Comprehensive Review. <i>Journal of Coloproctology</i> , 2023, 43, e227-e234.	0.1	0
709	Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn's Disease: A Pilot Study. <i>Biomedicines</i> , 2023, 11, 2575.	3.2	2
710	Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 499-512.e6.	4.4	0
713	Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation. <i>Biomedicine and Pharmacotherapy</i> , 2023, 168, 115706.	5.6	0
714	Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics. <i>Cell Reports Medicine</i> , 2024, 5, 101345.	6.5	1
715	Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis. <i>Scientific Reports</i> , 2024, 14, .	3.3	1
716	Allo-HSCT with TBI-based preconditioning for hepatosplenic T-cell lymphoma: two case reports and systematic review of literature. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
717	Terapia biológica en el adulto mayor con enfermedad inflamatoria intestinal: revisión narrativa. <i>Revista Universitas Medica</i> , 2024, 64, .	0.1	0
718	Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia. <i>Saudi Journal of Gastroenterology</i> , 0, , .	1.1	0
719	Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care. <i>Indian Journal of Gastroenterology</i> , 2024, 43, 36-47.	1.4	0

#	ARTICLE	IF	CITATIONS
720	Acute Cytomegalovirus Colitis Presenting As Exacerbation of Ulcerative Colitis: A Case Report. Cureus, 2024, , .	0.5	0